Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Multiple Myeloma 5Breast Neoplasms 5Prostatic Neoplasms 4Hematologic Neoplasms 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Neuroendocrine Tumors 3Neoplasm Metastasis 3Leukemia, Lymphocytic, Chronic, B-Cell 3Head and Neck Neoplasms 3Urothelial Cancer 2Thyroid Neoplasms 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neurofibromatosis 1 2Neurofibroma, Plexiform 2Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Endometrial Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Adenoma, Islet Cell 2von Hippel-Lindau Disease 1Uterine Neoplasms 1

Interventions

trastuzumab deruxtecan 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × HER2-Positive Primary Breast Cancer × 30 days × Clear all
NCT04622319 2026-05-15

DESTINY-Breast05

Daiichi Sankyo

Phase 3 Active not recruiting
1,600 enrolled 1 FDA
Breast

HER2-Positive Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡